The threat to NVO’s franchise from biosimilars is genuine, IMO. Insulin is the simplest of all proteins. Producing knockoffs of any of the currently marketed insulin analogs ought to be a piece of cake compared to the effort MNTA/NVS undertook for Lovenox and Copaxone.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.